IRIDEX (NASDAQ:IRIX) Now Covered by Analysts at assumed coverage on shares of IRIDEX (NASDAQ:IRIXFree Report) in a research report released on Thursday morning. The brokerage issued a hold rating on the medical equipment provider’s stock.

Separately, Stifel Nicolaus reaffirmed a hold rating and set a $2.00 target price on shares of IRIDEX in a report on Wednesday, May 15th.

Read Our Latest Analysis on IRIDEX

IRIDEX Price Performance

IRIDEX stock opened at $2.07 on Thursday. The business has a 50 day simple moving average of $2.44 and a 200 day simple moving average of $2.67. The company has a market capitalization of $33.64 million, a PE ratio of -3.09 and a beta of 0.83. IRIDEX has a one year low of $1.31 and a one year high of $3.65.

IRIDEX (NASDAQ:IRIXGet Free Report) last released its quarterly earnings results on Tuesday, May 14th. The medical equipment provider reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.09). IRIDEX had a negative net margin of 21.92% and a negative return on equity of 105.42%. The firm had revenue of $11.76 million during the quarter, compared to analyst estimates of $12.00 million. During the same quarter last year, the firm earned ($0.13) earnings per share. Equities analysts anticipate that IRIDEX will post -0.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On IRIDEX

A hedge fund recently raised its stake in IRIDEX stock. Perkins Capital Management Inc. lifted its holdings in IRIDEX Co. (NASDAQ:IRIXFree Report) by 13.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,300 shares of the medical equipment provider’s stock after purchasing an additional 5,200 shares during the quarter. Perkins Capital Management Inc. owned 0.28% of IRIDEX worth $135,000 as of its most recent SEC filing. 20.10% of the stock is owned by institutional investors.


(Get Free Report)

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.

Read More

Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with's FREE daily email newsletter.